Skip to main content
PMC home page
Gut logoLink to Gut
. 2000 Apr;46(4):464–467. doi: 10.1136/gut.46.4.464

Detection of upper gastrointestinal cancer in patients taking antisecretory therapy prior to gastroscopy

M Bramble 1, Z Suvakovic 1, A Hungin 1
PMCID: PMC1727877  PMID: 10716673

Abstract

BACKGROUND—The incidence of early gastric cancer has not increased despite better access to endoscopic facilities for general practitioners. Many patients receive a course of symptomatic treatment while waiting for gastroscopy.
AIMS—To ascertain the effect of antisecretory therapy on the diagnostic process and findings for patients with upper gastrointestinal cancer.
METHODS—A consecutive case study survey of the primary care records of 133 patients who had died of upper gastrointestinal cancer during 1995-97 in the South Tees health district in the north-east of England (population 300 000).
RESULTS—From the 133 patients identified, 116 had died from adenocarcinoma of the oesophagus (31) or stomach (85). Failure to reach the diagnosis of cancer at the index gastroscopy was associated with prior acid suppression therapy. Only one of 54 patients on no treatment or antacids alone was erroneously diagnosed as suffering from benign disease, whereas 22 of 62 patients treated with acid suppression were diagnosed as suffering from benign disease but at varying times later turned out to have adenocarcinoma. Twenty of 45 patients taking a proton pump inhibitor had a delayed diagnosis compared with two of 17 taking an H2 receptor antagonist. The commonest lesion seen at index gastroscopy in those in whom the diagnosis was initially missed was gastric ulcer. Healing occurred in six patients taking a proton pump inhibitor, despite their later diagnosis of malignancy.
CONCLUSIONS—The treatment of dyspeptic symptoms with acid suppression prior to gastroscopy masks and delays the detection of gastric and oesophageal adenocarcinoma on endoscopy in one third of patients.


Keywords: diagnosis; upper gastrointestinal cancer; gastric adenocarcinoma; oesophageal adenocarcinoma; gastroscopy; antisecretory therapy

Full Text

The Full Text of this article is available as a PDF (108.2 KB).

Figure 1  .

Figure 1  

Open in a new tab

Diagnosis and investigations in 133 patients with upper gastrointestinal cancer.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allum W. H., Powell D. J., McConkey C. C., Fielding J. W. Gastric cancer: a 25-year review. Br J Surg. 1989 Jun;76(6):535–540. doi: 10.1002/bjs.1800760604. [DOI] [PubMed] [Google Scholar]
  2. Axon A. T., Bell G. D., Jones R. H., Quine M. A., McCloy R. F. Guidelines on appropriate indications for upper gastrointestinal endoscopy. Working Party of the Joint Committee of the Royal College of Physicians of London, Royal College of Surgeons of England, Royal College of Anaesthetists, Association of Surgeons, the British Society of Gastroenterology, and the Thoracic Society of Great Britain. BMJ. 1995 Apr 1;310(6983):853–856. doi: 10.1136/bmj.310.6983.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cuschieri A., Fayers P., Fielding J., Craven J., Bancewicz J., Joypaul V., Cook P. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet. 1996 Apr 13;347(9007):995–999. doi: 10.1016/s0140-6736(96)90144-0. [DOI] [PubMed] [Google Scholar]
  4. Lagergren J., Bergström R., Lindgren A., Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825–831. doi: 10.1056/NEJM199903183401101. [DOI] [PubMed] [Google Scholar]
  5. Martin I. G., Young S., Sue-Ling H., Johnston D. Delays in the diagnosis of oesophagogastric cancer: a consecutive case series. BMJ. 1997 Feb 15;314(7079):467–470. doi: 10.1136/bmj.314.7079.467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Martin R. M., Lim A. G., Kerry S. M., Hilton S. R. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther. 1998 Aug;12(8):797–805. doi: 10.1046/j.1365-2036.1998.00374.x. [DOI] [PubMed] [Google Scholar]
  7. Sue-Ling H. M., Johnston D., Martin I. G., Dixon M. F., Lansdown M. R., McMahon M. J., Axon A. T. Gastric cancer: a curable disease in Britain. BMJ. 1993 Sep 4;307(6904):591–596. doi: 10.1136/bmj.307.6904.591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Suvakovic Z., Bramble M. G., Jones R., Wilson C., Idle N., Ryott J. Improving the detection rate of early gastric cancer requires more than open access gastroscopy: a five year study. Gut. 1997 Sep;41(3):308–313. doi: 10.1136/gut.41.3.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Taylor R. H., Menzies-Gow N., Lovell D., La Brooy S. J., Misiewicz J. J. Misleading response of malignant gastric ulcers to cimetidine. Lancet. 1978 Apr 1;1(8066):686–688. doi: 10.1016/s0140-6736(78)90799-7. [DOI] [PubMed] [Google Scholar]
  10. Tsukuma H., Mishima T., Oshima A. Prospective study of "early" gastric cancer. Int J Cancer. 1983 Apr 15;31(4):421–426. doi: 10.1002/ijc.2910310405. [DOI] [PubMed] [Google Scholar]
  11. Wayman J., Hayes N., Griffin S. M. The response of early gastric cancer to proton-pump inhibitors. N Engl J Med. 1998 Jun 25;338(26):1924–1925. doi: 10.1056/NEJM199806253382616. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES